Roquefort Therapeutics (LON:ROQ) Trading Up 16.1% – What’s Next?

Roquefort Therapeutics plc (LON:ROQ)’s stock price rose 16.1% during trading on Monday . The stock traded as high as GBX 2.10 ($0.03) and last traded at GBX 2.09 ($0.03). Approximately 5,286,537 shares were traded during trading, an increase of 71% from the average daily volume of 3,088,488 shares. The stock had previously closed at GBX 1.80 ($0.02).

Roquefort Therapeutics Trading Up 27.5 %

The company has a debt-to-equity ratio of 12.37, a quick ratio of 3.07 and a current ratio of 0.79. The company has a 50 day simple moving average of GBX 2.80 and a 200 day simple moving average of GBX 3.60. The company has a market capitalization of £2.93 million, a PE ratio of -1.90 and a beta of 0.05.

Insider Buying and Selling

In related news, insider Stephen Paul West acquired 400,000 shares of Roquefort Therapeutics stock in a transaction dated Tuesday, February 4th. The shares were acquired at an average cost of GBX 3 ($0.04) per share, for a total transaction of £12,000 ($15,511.89). 60.40% of the stock is currently owned by company insiders.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.